Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

984
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
984
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

471
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
471
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

146
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
146
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

107
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
107
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

16.1K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
16.1K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.2K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PPAR-γ modulation restores the adiponectin-AMPK-AKT axis to attenuate metabolic stress-associated alzheimer's pathology.

Molecular biology reports·2026
Same author

Oxidative Stress-Driven Mechanisms and Biomarkers of Drug-Induced Nephrotoxicity: Translational Insights and Therapeutic Implications.

Antioxidants (Basel, Switzerland)·2026
Same author

Development of berberine-loaded PEGylated liposomes: <i>in-vitro</i> and <i>ex-vivo</i> evaluation.

Drug development and industrial pharmacy·2026
Same author

Application of Box-Behnken design for the development of bilosome-mediated dual delivery of ascorbic acid and piperine: characterization, in silico and in vitro investigations.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

Phytochemical-Based Nanotherapeutics for Skin Cancer: A Critical Appraisal of Current Strategies, Challenges, and Future Perspectives.

Chemistry & biodiversity·2026
Same author

Retraction Note: Umbelliferone β-D-galactopyranoside from Aegle Marmelos (L.) corr. An ethnomedicinal plant with Antidiabetic, Antihyperlipidemic And Antioxidative activity.

BMC complementary medicine and therapies·2026

Related Experiment Video

Updated: Dec 27, 2025

Preparation of Gynura bicolor DC samples for High-Resolution Tandem Mass Spectrometry
07:16

Preparation of Gynura bicolor DC samples for High-Resolution Tandem Mass Spectrometry

Published on: February 2, 2024

935

Guggulipid: A Promising Multi-Purpose Herbal Medicinal Agent.

Md Afroz Ahmad1, Mohd Mujeeb2, Mohd Akhtar3

  • 1Department of Pharmacy, Integral University, Lucknow, India.

Drug Research
|February 29, 2020
PubMed
Summary

Guggulipid, derived from Commiphora wightii, offers a cost-effective herbal therapy with a wide therapeutic window. This review details its chemical, pharmacological, and toxicological properties for treating inflammation, obesity, and lipid disorders.

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.6K

Related Experiment Videos

Last Updated: Dec 27, 2025

Preparation of Gynura bicolor DC samples for High-Resolution Tandem Mass Spectrometry
07:16

Preparation of Gynura bicolor DC samples for High-Resolution Tandem Mass Spectrometry

Published on: February 2, 2024

935
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.6K

Area of Science:

  • Phytochemistry
  • Pharmacology
  • Toxicology

Background:

  • Herbal medicines are valued for their safety, efficacy, and cost-effectiveness.
  • Guggulipid is an extract from Commiphora wightii resin, containing active compounds like E- and Z-guggulsterone.
  • Historically, guggul has been used for arthritis, inflammation, obesity, and cardiovascular conditions.

Purpose of the Study:

  • To review the chemical, pharmacological, and toxicological profiles of guggulipid.
  • To consolidate existing research on the therapeutic potential of guggulipid.
  • To highlight guggulipid's suitability as a natural product for various health disorders.

Main Methods:

  • Literature review of scientific studies on guggulipid.
  • Analysis of chemical composition and active compounds.
  • Compilation of pharmacological and toxicological data.

Main Results:

  • Guggulipid contains E- and Z-guggulsterone isomers as key active compounds.
  • Demonstrated therapeutic effects in treating inflammation, pain, wounds, liver disorders, and acne.
  • Possesses a favorable safety profile with a high therapeutic window.

Conclusions:

  • Guggulipid is a promising natural product with diverse therapeutic applications.
  • Its established pharmacological activities support its use in managing various health conditions.
  • Further research can validate its efficacy and safety for specific treatments.